New combination antibiotic for serious infections

Zavicefta (ceftazidime/avibactam) is a new combination antibiotic for the treatment of serious Gram-negative bacterial infections requiring hospitalisation.

Ceftazidime/avibactam is active against pathogens including Enterobacteriaceae and Pseudomonas aeruginosa. | iSTOCK
Ceftazidime/avibactam is active against pathogens including Enterobacteriaceae and Pseudomonas aeruginosa. | iSTOCK

Zavicefta is given by intravenous infusion to treat complicated intra-abdominal infections, complicated urinary tract infections including pyelonephritis, and hospital-acquired pneumonia including ventilator-associated pneumonia. It can also be used in the treatment of aerobic Gram-negative infections in patients with limited treatment options.

Ceftazidime is an established third-generation cephalosporin. The addition of avibactam protects ceftazidime against degradation by bacterial β-lactamases.

According to the manufacturer, Zavicefta has been developed in response to the urgent need for new antibiotics to treat serious infections that are becoming increasingly resistant, such as multi-drug resistant Pseudomonas aeruginosa, carbapenem-resistant Gram-negative pathogens, and ESBL-producing Enterobacteriaceae.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Metformin use during pregnancy linked to reduced gestational weight gain

Metformin use during pregnancy linked to reduced gestational weight gain

Exposure to metformin versus other treatments during...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...